Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 21, 2023

Myeloablative Total Body Irradiation Plus Fludarabine or Cyclophosphamide as Conditioning for Patients With AML Undergoing Allogeneic HCT

American Journal of Hematology


Additional Info

Disclosure statements are available on the authors' profiles:

American Journal of Hematology
Fludarabine versus cyclophospamide in combination with myeloablative total body irradiation as conditioning for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Am. J. Hematol 2023 Jan 10;[EPub Ahead of Print], S Giebel, M Labopin, T Schroeder, R Swoboda, J Maertens, JH Bourhis, G Grillo, U Salmenniemi, I Hilgendorf, N Kröger, X Poiré, JJ Cornelissen, M Arat, B Savani, A Spyridonidis, A Nagler, M Mohty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading